Irazu Oncology
Irazu Oncology is a biotechnology company founded in 2022, dedicated to developing next-generation cancer immunotherapies using proprietary Outer Membrane Vesicles (OMV) platform. The company's mission is to create accessible, affordable, and effective cancer treatments by harnessing engineered bacterial nanoparticles to deliver cancer antigens, activating robust immune responses. Their lead candidate, IRZ-01, targets multiple solid tumor types and aims to provide immediate treatment options following diagnosis. The company is led by a team with over 100 years of drug development experience and is supported by notable investors and research institutions.
Industries
Nr. of Employees
small (1-50)
Irazu Oncology
Baltimore, Maryland, United States, North America
Products
IRZ-01 (OMV-based cancer vaccine candidate)
A preclinical vaccine candidate using an OMV-derived platform engineered to present tumor-associated antigens (examples cited: MUC1 and CEA) intended for multiple solid tumor indications; reported preclinical efficacy includes complete tumor remissions and protective immune responses against recurrence.
IRZ-01 (OMV-based cancer vaccine candidate)
A preclinical vaccine candidate using an OMV-derived platform engineered to present tumor-associated antigens (examples cited: MUC1 and CEA) intended for multiple solid tumor indications; reported preclinical efficacy includes complete tumor remissions and protective immune responses against recurrence.
Expertise Areas
- Cancer vaccine development
- Preclinical oncology and tumor immunology
- Antigen targeting and selection
- Bioprocess scale-up for microbial-derived therapeutics
Key Technologies
- Bacterial outer membrane vesicles (OMVs)
- Engineered bacterial-derived nanoparticles
- Tumor-associated antigen targeting (e.g., MUC1, CEA)
- Nanoparticle size engineering for lymphatic delivery